Cory Renauer
Value, research analyst, biotech, small-cap

Sangamo Engineering Genetic Cures

Sangamo Biosciences (NASDAQ:SGMO) is a not yet profitable biotech developing gene regulating biotherapeutics for unmet medical needs. Its proprietary technology platform allows Sangamo to modify naturally occurring zinc finger DNA-binding proteins (ZFPs) into proteins that can modify, activate or deactivate specific DNA sequences.

(click to enlarge)

Image Source: Sangamo SEC filings

Before going any further, it's important to understand that I am providing a very simplified explanation of Sangamo's technology and the science behind it. My intention is to provide investors with enough background to understand the company's potential advantage over competitors, not to administer a university level genetics course. If you want to know more, I suggest visiting the company's website and 10-K filings for far more...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details